AIMOVIG Injection for Preventive Treatment of Migraine in Adults

AIMOVIG (erenumab-aooe) is a prescription medication given as an injection under the skin, used to help prevent migraine headaches in adults. It belongs to a class of drugs that block a molecule involved in migraine development.

AIMOVIG is approved for the preventive treatment of migraine in adults to reduce the frequency of migraine attacks.

erenumab-aooe

AIMOVIG is a monoclonal antibody that binds specifically to the calcitonin gene-related peptide (CGRP) receptor. By blocking this receptor, it helps prevent the biological processes that lead to migraines.

Recommended Dose

• 70 mg injected subcutaneously once a month is the usual dose.
• Some patients may benefit from increasing the dose to 140 mg once monthly.

Administration Instructions

• Inject under the skin of the abdomen, thigh, or upper arm using the single-dose prefilled autoinjector or syringe.
• Before injection, allow the medicine to sit at room temperature for at least 30 minutes, away from direct sunlight. Do not use external heat sources.
• Do not shake the solution.
• Check for cloudiness, discoloration, flakes, or particles. Do not use if present.
• Do not inject into areas that are tender, bruised, red, or hard.
• If you miss a dose, give it as soon as possible, then continue monthly dosing from that date.

Patient Training

Patients and caregivers should receive proper training on injection technique and aseptic measures before self-administration.

AIMOVIG is contraindicated in patients with a serious hypersensitivity to erenumab-aooe or any component of the formulation, including severe allergic reactions such as anaphylaxis and angioedema.

Serious Warnings and Precautions

• Hypersensitivity Reactions: Severe allergic reactions, including anaphylaxis and angioedema, can occur. Discontinue AIMOVIG and seek immediate medical treatment if these occur.
• Constipation: Serious constipation and related complications have been reported, sometimes requiring hospitalization or surgery. Monitor for severe constipation and manage appropriately.
• Hypertension: New or worsening high blood pressure may develop, often within the first week of treatment. Monitor blood pressure and consider stopping AIMOVIG if no other cause is identified.
• Raynaud's Phenomenon: New or worsening symptoms such as cold, numb, or painful fingers or toes have been reported. Discontinue AIMOVIG if such symptoms develop and consult a healthcare provider.

Common Side Effects

• Injection site reactions (such as pain, redness, or itching), occurring in about 5-6% of patients.
• Constipation, reported in about 1-3% of patients.
• Muscle cramps or spasms (less common).

Postmarketing Reports

• Hypersensitivity reactions including rash, angioedema, and anaphylaxis.
• Serious constipation with complications.
• Oral mucosal ulcers.
• Rash and hair loss (alopecia).
• High blood pressure.
• Raynaud's phenomenon.

Pregnancy

There are no adequate data on use in pregnant women. Animal studies in monkeys showed no adverse effects on offspring at exposures greater than those in humans. Women with migraine may have an increased risk of pregnancy-related hypertension.

A pregnancy exposure registry exists for women taking AIMOVIG during pregnancy.

Lactation

It is unknown if AIMOVIG is present in human milk or affects the breastfed infant. Benefits of breastfeeding should be considered along with the mother’s need for AIMOVIG.

Store AIMOVIG injection refrigerated and protect it from direct sunlight. Before injection, allow it to reach room temperature for at least 30 minutes. Do not warm it with heat sources or shake the vial.